Apellis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell APLS and other ETFs, options, and stocks.

About APLS

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. 

CEO
Cedric Francois
CEOCedric Francois
Employees
739
Employees739
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2009
Founded2009
Employees
739
Employees739

APLS Key Statistics

Market cap
5.17B
Market cap5.17B
Price-Earnings ratio
234.40
Price-Earnings ratio234.40
Dividend yield
Dividend yield
Average volume
15.01M
Average volume15.01M
High today
$40.48
High today$40.48
Low today
$40.31
Low today$40.31
Open price
$40.37
Open price$40.37
Volume
10.33M
Volume10.33M
52 Week high
$40.48
52 Week high$40.48
52 Week low
$16.10
52 Week low$16.10

Stock Snapshot

As of today, Apellis Pharmaceuticals(APLS) shares are valued at $40.37. The company's market cap stands at 5.17B, with a P/E ratio of 234.40.

On 2026-04-03, Apellis Pharmaceuticals(APLS) stock traded between a low of $40.31 and a high of $40.48. Shares are currently priced at $40.37, which is +0.1% above the low and -0.3% below the high.

Apellis Pharmaceuticals(APLS) shares are trading with a volume of 10.33M, against a daily average of 15.01M.

In the last year, Apellis Pharmaceuticals(APLS) shares hit a 52-week high of $40.48 and a 52-week low of $16.10.

In the last year, Apellis Pharmaceuticals(APLS) shares hit a 52-week high of $40.48 and a 52-week low of $16.10.

APLS News

Nasdaq 2d
Apellis Pharmaceuticals Moves 135.4% Higher: Will This Strength Last?

Apellis Pharmaceuticals, Inc. (APLS) shares rallied 135.4% in the last trading session to close at $40.23. This move can be attributable to notable volume with...

Apellis Pharmaceuticals Moves 135.4% Higher: Will This Strength Last?
TipRanks 2d
Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on APLS stock, giving a Hold rating today. End of Quarter Sale - 50% Off TipRanks Unlock hed...

TipRanks 2d
Apellis Pharmaceuticals to be Acquired by Biogen in Merger

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

90%

of 21 ratings
Buy
9.5%
Hold
90.5%
Sell
0%

More APLS News

Benzinga 3d
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were higher, with the Dow Jones index gaining more than 600 points on Tuesday. Apellis Pharmaceuticals shares jumped 136.4% to $40.40 on Tuesday....

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

People also own

Based on the portfolios of people who own APLS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.